Loading…
Loading…
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City that attracts over 1,000 global experts across key target call points HINGHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, which is experiencing strong interest from physicians and hospital executives following the commencement of the Full Market Release of LIBERTY at the recent Society of Interventional Radiology (SIR) annual meeting, has since won accounts in key sales territories, including two accounts that participated in the ACCESS-PVI pivotal clinical trial.
Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.
BOSTON--(BUSINESS WIRE)-- #AFSymposium2026--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, where new clinical data and physician experiences will highlight how vMap can help improve procedural efficiency, enhance arrhythmia termination, and help enable post-ablation non-inducibility. At this year's meeting, a featured study titled “High Procedural Efficiency and Arrhythmia Non-Inducibil.
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
Ultra-short treasuries are becoming more relevant and attractive in the current environment than in years past. As advisors look to bolster portfolios with fixed income ETFs, the lesser-known Invesco VRDO Tax-Free ETF (PVI) and the Invesco Treasury Collateral ETF (CLTL) should be considered.
SPDR Bloomberg 1-3 Month T-Bill ETF (BIL), Invesco DB US Dollar Index Bullish Fund (UUP), iShares Treasury Floating Rate Bond ETF (TFLO), iMGP DBi Managed Futures Strategy ETF (DBMF) and Invesco VRDO Tax-Free ETF (PVI) have been the leaders amid the market turmoil.
Investors looking for less volatility in their portfolio may find value in augmenting their portfolios with one of Invesco's most stable fixed income offerings.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for PVI and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.